Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals

Benzinga_recent_news02:19

Regenxbio Inc. (NASDAQ:RGNX) shares are down on Wednesday after the company reported new interim data from its Phase 1/2 AFFINITY DUCHENNE trial of RGX-202. • Regenxbio stock is among today’s ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618942920?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-12 02:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618942920","market":"hk","top_or_hot":-1,"title":"Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals","media":"Benzinga_recent_news","content":"<div>\n<p>Regenxbio Inc. (NASDAQ:RGNX) shares are down on Wednesday after the company reported new interim data from its Phase 1/2 AFFINITY DUCHENNE trial of RGX-202.\n      • Regenxbio stock is among today’s ...</p>\n\n<a href=\"https://www.benzinga.com/markets/biotech/26/03/51196009/regenxbio-reports-duchenne-gene-therapy-progress-as-stock-slides-on-mixed-signals\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-12 02:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/biotech/26/03/51196009/regenxbio-reports-duchenne-gene-therapy-progress-as-stock-slides-on-mixed-signals><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regenxbio Inc. (NASDAQ:RGNX) shares are down on Wednesday after the company reported new interim data from its Phase 1/2 AFFINITY DUCHENNE trial of RGX-202.\n      • Regenxbio stock is among today’s ...</p>\n\n<a href=\"https://www.benzinga.com/markets/biotech/26/03/51196009/regenxbio-reports-duchenne-gene-therapy-progress-as-stock-slides-on-mixed-signals\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://www.benzinga.com/markets/biotech/26/03/51196009/regenxbio-reports-duchenne-gene-therapy-progress-as-stock-slides-on-mixed-signals","article_id":"2618942920","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/11/Gene-therapy-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/biotech/26/03/51196009/regenxbio-reports-duchenne-gene-therapy-progress-as-stock-slides-on-mixed-signals","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618942920","pubTimestamp":1773253140,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Regenxbio releases new Duchenne trial data showing improved motor function and stable heart measures in early-stage patients.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","PRGS":"Progress Software Corporation","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","CRL":"查尔斯河","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4588":"碎股","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4097":"系统软件","BK4121":"生命科学工具和服务","BK4217":"自存仓储房地产信托","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4563":"昨日强势股","BK4139":"生物科技","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","BK4530":"医药外包概念","RGNX":"Regenxbio Inc","SMA":"Smartstop Self Storage REIT Inc"},"translate_title":"Regenxbio报告杜兴基因疗法取得进展，股价因混合信号而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1.5,"CRL":1,"RGNX":1.5,"SMA":1},"content_text":"Regenxbio Inc. (NASDAQ:RGNX) shares are down on Wednesday after the company reported new interim data from its Phase 1/2 AFFINITY DUCHENNE trial of RGX-202.\n      • Regenxbio stock is among today’s weakest performers. Why is RGNX stock dropping?\nThe latest data from REGENXBIO indicate a favorable safety and efficacy profile for RGX-202, a potential gene therapy for Duchenne muscular dystrophy.\nInterim results show that pivotal dose participants improved an average of +4.9 points on the North Star Ambulatory Assessment (NSAA) compared to expected disease progression, highlighting the therapy’s potential impact.\nNSAA measures functional motor abilities.\nIn addition, the trial demonstrated cardiac stability among participants, with key measures showing no significant decline over the treatment period.\nThe company expects to share topline pivotal data in the early second quarter of 2026 and plans to request a pre-BLA meeting with the FDA in mid-2026.\nBiomarker data continues to support consistent, high expression and transduction of RGX-202 microdystrophin (n=13).\nNew data from an additional patient, aged 3.6 at dosing, had a microdystrophin expression level of 51.2% at week 12.\nIn February, the  U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to the company’s Biologics License Application (BLA) for RGX-121, for Mucopolysaccharidosis II (MPS II), an ultra-rare neurodegenerative disease also known as Hunter syndrome.\nThe stock is currently trading 7.5% above its 20-day simple moving average (SMA) but is 22.6% below its 100-day SMA, indicating a struggle to maintain momentum in the longer term.\nOver the past 12 months, shares have increased by 52.39%, and they are currently positioned closer to their 52-week lows than highs.\nThe RSI is at 51.63, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD shows a value of -0.4431, with the signal line at -0.7903, indicating bullish momentum as the MACD is above the signal line.\nThe combination of neutral RSI and bullish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in direction.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $28.70. Recent analyst moves include:\nBelow is the Benzinga Edge scorecard for REGENXBIO, highlighting its strengths and weaknesses compared to the broader market:\nThe Verdict: REGENXBIO’s Benzinga Edge signal reveals a classic “High-Flyer” setup. While the Momentum (66.13) confirms the strong trend, the company-specific challenges highlighted in the latest trial data may require close monitoring.\nRGNX Price Action: Regenxbio shares were down 4.44% at $9.46 at the time of publication on Wednesday, according to Benzinga Pro data.\nImage via Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618942920","isCrawlerRequest":true}